株探米国株
英語
エドガーで原本を確認する
false2023Q3000163156912/31seven years, three monthshttp://fasb.org/us-gaap/2023#OtherAssetshttp://fasb.org/us-gaap/2023#OtherAssetshttp://fasb.org/us-gaap/2023#OtherLiabilitieshttp://fasb.org/us-gaap/2023#OtherLiabilitieshttp://fasb.org/us-gaap/2023#InterestExpensehttp://fasb.org/us-gaap/2023#InterestExpensehttp://fasb.org/us-gaap/2023#InterestExpensehttp://fasb.org/us-gaap/2023#InterestExpensehttp://fasb.org/us-gaap/2023#OtherLiabilitieshttp://fasb.org/us-gaap/2023#OtherLiabilitieshttp://fasb.org/us-gaap/2023#OtherLiabilitieshttp://fasb.org/us-gaap/2023#OtherLiabilities00016315692023-01-012023-09-3000016315692023-10-25xbrli:shares00016315692023-09-30iso4217:USD00016315692022-12-31iso4217:USDxbrli:shares00016315692023-07-012023-09-3000016315692022-07-012022-09-3000016315692022-01-012022-09-300001631569us-gaap:PreferredStockMember2023-06-300001631569us-gaap:CommonStockMember2023-06-300001631569us-gaap:AdditionalPaidInCapitalMember2023-06-300001631569chct:CumulativeNetIncomeDeficitMember2023-06-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001631569chct:CumulativeDividendsMember2023-06-3000016315692023-06-300001631569us-gaap:CommonStockMember2023-07-012023-09-300001631569us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001631569chct:CumulativeNetIncomeDeficitMember2023-07-012023-09-300001631569chct:CumulativeDividendsMember2023-07-012023-09-300001631569us-gaap:PreferredStockMember2023-09-300001631569us-gaap:CommonStockMember2023-09-300001631569us-gaap:AdditionalPaidInCapitalMember2023-09-300001631569chct:CumulativeNetIncomeDeficitMember2023-09-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001631569chct:CumulativeDividendsMember2023-09-300001631569us-gaap:PreferredStockMember2022-12-310001631569us-gaap:CommonStockMember2022-12-310001631569us-gaap:AdditionalPaidInCapitalMember2022-12-310001631569chct:CumulativeNetIncomeDeficitMember2022-12-310001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001631569chct:CumulativeDividendsMember2022-12-310001631569us-gaap:CommonStockMember2023-01-012023-09-300001631569us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001631569chct:CumulativeNetIncomeDeficitMember2023-01-012023-09-300001631569chct:CumulativeDividendsMember2023-01-012023-09-300001631569us-gaap:PreferredStockMember2022-06-300001631569us-gaap:CommonStockMember2022-06-300001631569us-gaap:AdditionalPaidInCapitalMember2022-06-300001631569chct:CumulativeNetIncomeDeficitMember2022-06-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001631569chct:CumulativeDividendsMember2022-06-3000016315692022-06-300001631569us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001631569us-gaap:CommonStockMember2022-07-012022-09-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001631569chct:CumulativeNetIncomeDeficitMember2022-07-012022-09-300001631569chct:CumulativeDividendsMember2022-07-012022-09-300001631569us-gaap:PreferredStockMember2022-09-300001631569us-gaap:CommonStockMember2022-09-300001631569us-gaap:AdditionalPaidInCapitalMember2022-09-300001631569chct:CumulativeNetIncomeDeficitMember2022-09-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001631569chct:CumulativeDividendsMember2022-09-3000016315692022-09-300001631569us-gaap:PreferredStockMember2021-12-310001631569us-gaap:CommonStockMember2021-12-310001631569us-gaap:AdditionalPaidInCapitalMember2021-12-310001631569chct:CumulativeNetIncomeDeficitMember2021-12-310001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001631569chct:CumulativeDividendsMember2021-12-3100016315692021-12-310001631569us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001631569us-gaap:CommonStockMember2022-01-012022-09-300001631569us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300001631569chct:CumulativeNetIncomeDeficitMember2022-01-012022-09-300001631569chct:CumulativeDividendsMember2022-01-012022-09-30chct:real_estate_propertychct:stateutr:sqftxbrli:pure0001631569us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2023-09-300001631569chct:MedicalOfficeBuildingMember2023-09-300001631569chct:InpatientRehabilitationHospitalMember2023-09-300001631569chct:AcuteInpatientBehavioralMember2023-09-300001631569chct:SpecialtyCentersMember2023-09-300001631569chct:PhysicianClinicsMember2023-09-300001631569chct:SurgicalCentersandHospitalsMember2023-09-300001631569chct:BehavioralFacilitiesMember2023-09-300001631569chct:LongTermAcuteCareFacilityMember2023-09-300001631569stpr:TX2023-09-300001631569stpr:IL2023-09-300001631569stpr:OH2023-09-300001631569stpr:FL2023-09-300001631569stpr:PA2023-09-300001631569chct:OtherStatesMember2023-09-300001631569chct:LifePointHealthMember2023-09-300001631569chct:USHealthVestMember2023-09-300001631569chct:OtherTenantMember2023-09-300001631569chct:EverestRehabilitationMember2023-03-310001631569chct:GenesisCareMemberstpr:NC2023-06-300001631569stpr:FLchct:GenesisCareMember2023-09-300001631569chct:SoleTenantPropertyMemberchct:GenesisCareMember2023-09-300001631569chct:MultiTenantPropertyMemberchct:GenesisCareMember2023-09-300001631569chct:GenesisCareMember2023-09-300001631569chct:NorthCarolinaAndFloridaMemberchct:GenesisCareMember2023-09-30chct:lease0001631569chct:FourRealEstatePropertyMember2023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ32023Member2023-07-012023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ22023Member2023-04-012023-06-30chct:land_parcel0001631569chct:AcquisitionsOfPropertiesDuringQ22023Member2023-01-012023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ12023Member2023-01-012023-03-310001631569chct:AcquisitionsOfPropertiesDuringQ12023Member2023-01-012023-09-300001631569chct:LagrangeGAMemberchct:AcquisitionsOfPropertiesDuringQ12023Member2023-01-012023-09-300001631569chct:LagrangeGAMemberchct:AcquisitionsOfPropertiesDuringQ12023Member2023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ12023Memberchct:WestPointGAMember2023-01-012023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ12023Memberchct:WestPointGAMember2023-09-300001631569chct:CantonOHMemberchct:AcquisitionsOfPropertiesDuringQ12023Member2023-01-012023-09-300001631569chct:CantonOHMemberchct:AcquisitionsOfPropertiesDuringQ12023Member2023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ12023Memberchct:ScrantonPAMember2023-01-012023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ12023Memberchct:ScrantonPAMember2023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ12023Memberchct:ScrantonPAOneMember2023-01-012023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ12023Memberchct:ScrantonPAOneMember2023-09-300001631569chct:LaGrangeGAOneMemberchct:AcquisitionsOfPropertiesDuringQ12023Member2023-01-012023-09-300001631569chct:LaGrangeGAOneMemberchct:AcquisitionsOfPropertiesDuringQ12023Member2023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ12023Memberchct:LaGrangeGATwoMember2023-01-012023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ12023Memberchct:LaGrangeGATwoMember2023-09-300001631569chct:LakelandFLMemberchct:AcquisitionsOfPropertiesDuringQ22023Member2023-01-012023-09-300001631569chct:LakelandFLMemberchct:AcquisitionsOfPropertiesDuringQ22023Member2023-09-300001631569chct:HermitagePAMemberchct:AcquisitionsOfPropertiesDuringQ22023Member2023-01-012023-09-300001631569chct:HermitagePAMemberchct:AcquisitionsOfPropertiesDuringQ22023Member2023-09-300001631569chct:SanAntonioTXMemberchct:AcquisitionsOfPropertiesDuringQ22023Member2023-01-012023-09-300001631569chct:SanAntonioTXMemberchct:AcquisitionsOfPropertiesDuringQ22023Member2023-09-300001631569chct:ClintonMDMemberchct:AcquisitionsOfPropertiesDuringQ22023Member2023-01-012023-09-300001631569chct:ClintonMDMemberchct:AcquisitionsOfPropertiesDuringQ22023Member2023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ32023Memberchct:FtMyersFLMember2023-01-012023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ32023Memberchct:FtMyersFLMember2023-09-300001631569chct:FtMyersFLOneMemberchct:AcquisitionsOfPropertiesDuringQ32023Member2023-01-012023-09-300001631569chct:FtMyersFLOneMemberchct:AcquisitionsOfPropertiesDuringQ32023Member2023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ32023Memberchct:ImmokaleeFLMember2023-01-012023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ32023Memberchct:ImmokaleeFLMember2023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ32023Memberchct:ElPasoTXMember2023-01-012023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ32023Memberchct:ElPasoTXMember2023-09-300001631569chct:BeaverPAMemberchct:AcquisitionsOfPropertiesDuringQ32023Member2023-01-012023-09-300001631569chct:BeaverPAMemberchct:AcquisitionsOfPropertiesDuringQ32023Member2023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ32023Memberchct:WestlakeOHMember2023-01-012023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ32023Memberchct:WestlakeOHMember2023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ32023Memberchct:NewcastlePAMember2023-01-012023-09-300001631569chct:AcquisitionsOfPropertiesDuringQ32023Memberchct:NewcastlePAMember2023-09-300001631569chct:AcquisitionsOfPropertiesDuring2023Member2023-01-012023-09-300001631569chct:AcquisitionsOfPropertiesDuring2023Member2023-09-300001631569us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember2023-09-300001631569us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMemberus-gaap:LandAndLandImprovementsMember2023-09-300001631569us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMemberus-gaap:BuildingAndBuildingImprovementsMember2023-09-300001631569us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMemberus-gaap:LeasesAcquiredInPlaceMember2023-09-300001631569us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMemberus-gaap:AboveMarketLeasesMember2023-09-300001631569us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember2023-01-012023-09-3000016315692023-04-012023-06-300001631569chct:InterestAndOtherIncomeMember2023-04-012023-06-300001631569us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2023-07-012023-09-300001631569us-gaap:LineOfCreditMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2023-09-300001631569us-gaap:LineOfCreditMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-12-310001631569chct:TermLoanMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A3TermLoanMember2023-09-300001631569chct:TermLoanMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A3TermLoanMember2022-12-310001631569chct:TermLoanMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A4TermLoanMember2023-09-300001631569chct:TermLoanMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A4TermLoanMember2022-12-310001631569chct:TermLoanMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A5TermLoanMember2023-09-300001631569chct:TermLoanMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A5TermLoanMember2022-12-310001631569us-gaap:MortgagesMember2023-09-300001631569us-gaap:MortgagesMember2022-12-310001631569chct:TermLoanMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A5TermLoanMember2022-12-140001631569chct:TermLoanMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A2TermLoanMember2022-12-142022-12-140001631569chct:TermLoanMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A2TermLoanMember2022-12-140001631569chct:ThirdAmendedAndRestatedCreditFacilityMemberchct:CreditFacilityAccordionFeatureMember2022-12-140001631569us-gaap:LineOfCreditMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-12-140001631569us-gaap:LineOfCreditMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:TermLoanMember2022-12-14chct:option0001631569us-gaap:LineOfCreditMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-12-142022-12-140001631569chct:TermLoanMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A3TermLoanMember2022-12-142022-12-140001631569chct:TermLoanMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A3TermLoanMember2022-12-140001631569chct:TermLoanMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A4TermLoanMember2022-12-142022-12-140001631569chct:TermLoanMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A4TermLoanMember2022-12-140001631569us-gaap:LineOfCreditMemberchct:ThirdAmendedAndRestatedCreditFacilityMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-12-142022-12-140001631569us-gaap:LineOfCreditMemberchct:ThirdAmendedAndRestatedCreditFacilityMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-12-142022-12-140001631569us-gaap:LineOfCreditMemberchct:ThirdAmendedAndRestatedCreditFacilityMembersrt:MinimumMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMember2022-12-142022-12-140001631569us-gaap:LineOfCreditMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberus-gaap:BaseRateMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2022-12-142022-12-140001631569us-gaap:LineOfCreditMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:RevolvingCreditFacilityUnusedBorrowingCapacityRate1Member2022-12-142022-12-140001631569us-gaap:LineOfCreditMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:RevolvingCreditFacilityUnusedBorrowingCapacityRate2Member2022-12-142022-12-140001631569chct:TermLoanMemberchct:FirstAmendedAndRestatedCreditFacilityMembersrt:MinimumMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-12-142022-12-140001631569chct:TermLoanMemberchct:FirstAmendedAndRestatedCreditFacilityMembersrt:MaximumMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-12-142022-12-140001631569chct:TermLoanMemberchct:FirstAmendedAndRestatedCreditFacilityMembersrt:MinimumMemberus-gaap:BaseRateMember2022-12-142022-12-140001631569chct:TermLoanMemberchct:FirstAmendedAndRestatedCreditFacilityMemberus-gaap:BaseRateMembersrt:MaximumMember2022-12-142022-12-140001631569chct:TermLoanMemberchct:FirstAmendedAndRestatedCreditFacilityMember2023-09-300001631569us-gaap:MortgagesMemberus-gaap:BuildingMember2023-09-300001631569chct:TermLoanMemberchct:ThirdAmendedAndRestatedCreditFacilityMemberchct:A5TermLoanMember2022-12-142022-12-140001631569us-gaap:CashFlowHedgingMemberus-gaap:InterestRateContractMember2023-09-30chct:derivative_instrument0001631569us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2023-09-300001631569us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2023-09-300001631569us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2022-12-310001631569us-gaap:CashFlowHedgingMemberus-gaap:InterestRateContractMember2023-07-012023-09-300001631569us-gaap:CashFlowHedgingMemberus-gaap:InterestRateContractMember2022-07-012022-09-300001631569us-gaap:CashFlowHedgingMemberus-gaap:InterestRateContractMember2023-01-012023-09-300001631569us-gaap:CashFlowHedgingMemberus-gaap:InterestRateContractMember2022-01-012022-09-300001631569us-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateContractMember2023-07-012023-09-300001631569us-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateContractMember2022-07-012022-09-300001631569us-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateContractMember2023-01-012023-09-300001631569us-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateContractMember2022-01-012022-09-3000016315692022-01-012022-12-310001631569chct:AtTheMarketOfferingProgramMemberus-gaap:CommonStockMember2023-01-012023-09-300001631569chct:AtTheMarketOfferingProgramMemberus-gaap:CommonStockMember2023-09-300001631569chct:AtTheMarketOfferingProgramMemberus-gaap:CommonStockMember2023-07-012023-09-300001631569us-gaap:RestrictedStockMemberchct:A2014IncentivePlanMember2023-06-300001631569us-gaap:RestrictedStockMemberchct:A2014IncentivePlanMember2022-06-300001631569us-gaap:RestrictedStockMemberchct:A2014IncentivePlanMember2022-12-310001631569us-gaap:RestrictedStockMemberchct:A2014IncentivePlanMember2021-12-310001631569chct:A2014IncentivePlanMemberchct:RestrictedCommonStockStockinLieuofCompensationMember2023-07-012023-09-300001631569chct:A2014IncentivePlanMemberchct:RestrictedCommonStockStockinLieuofCompensationMember2022-07-012022-09-300001631569chct:A2014IncentivePlanMemberchct:RestrictedCommonStockStockinLieuofCompensationMember2023-01-012023-09-300001631569chct:A2014IncentivePlanMemberchct:RestrictedCommonStockStockinLieuofCompensationMember2022-01-012022-09-300001631569chct:A2014IncentivePlanMemberchct:RestrictedCommonStockStockAwardsMember2023-07-012023-09-300001631569chct:A2014IncentivePlanMemberchct:RestrictedCommonStockStockAwardsMember2022-07-012022-09-300001631569chct:A2014IncentivePlanMemberchct:RestrictedCommonStockStockAwardsMember2023-01-012023-09-300001631569chct:A2014IncentivePlanMemberchct:RestrictedCommonStockStockAwardsMember2022-01-012022-09-300001631569us-gaap:RestrictedStockMemberchct:A2014IncentivePlanMember2023-07-012023-09-300001631569us-gaap:RestrictedStockMemberchct:A2014IncentivePlanMember2022-07-012022-09-300001631569us-gaap:RestrictedStockMemberchct:A2014IncentivePlanMember2023-01-012023-09-300001631569us-gaap:RestrictedStockMemberchct:A2014IncentivePlanMember2022-01-012022-09-300001631569us-gaap:RestrictedStockMemberchct:A2014IncentivePlanMember2023-09-300001631569us-gaap:RestrictedStockMemberchct:A2014IncentivePlanMember2022-09-300001631569srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockMember2023-01-012023-09-300001631569srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockMember2023-01-012023-03-310001631569us-gaap:NotesReceivableMemberchct:NoteReceivable1Member2023-09-300001631569us-gaap:NotesReceivableMemberchct:NoteReceivable1Member2022-12-310001631569chct:NoteReceivable1Memberchct:LongTermAcuteCareFacilityMember2023-01-012023-09-30chct:hospital0001631569chct:InpatientRehabilitationHospitalMemberchct:NoteReceivable1Member2023-01-012023-09-300001631569us-gaap:NotesReceivableMemberchct:NoteReceivable1Member2023-01-012023-09-300001631569us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberchct:NoteReceivable3Member2022-12-310001631569us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberchct:NoteReceivable3Member2023-09-300001631569chct:NoteReceivable2Memberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-09-300001631569chct:NoteReceivable2Memberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2022-12-310001631569chct:GeriatricBehavioralHospitalMember2023-01-012023-09-300001631569us-gaap:NotesReceivableMember2023-01-012023-09-300001631569us-gaap:NotesReceivableMemberus-gaap:RevolvingCreditFacilityMember2023-01-012023-09-300001631569us-gaap:NotesReceivableMember2023-09-300001631569chct:NoteReceivable4Memberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-09-300001631569chct:NoteReceivable4Memberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2022-12-310001631569chct:NoteReceivable4Memberus-gaap:NotesReceivableMember2023-01-012023-09-300001631569chct:NoteReceivable4Memberus-gaap:RevolvingCreditFacilityMember2023-01-012023-09-300001631569chct:NoteReceivable4Memberus-gaap:RevolvingCreditFacilityMember2023-09-300001631569us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberchct:NoteReceivable1Member2023-09-300001631569us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001631569us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001631569us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001631569us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001631569us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:InterestRateSwapMember2023-09-300001631569us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:InterestRateSwapMember2023-09-300001631569us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:InterestRateSwapMember2022-12-310001631569us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:InterestRateSwapMember2022-12-310001631569us-gaap:SubsequentEventMember2023-10-262023-10-260001631569chct:MedicalOfficeBuildingMemberus-gaap:SubsequentEventMember2023-10-012023-10-310001631569us-gaap:SubsequentEventMember2023-10-012023-10-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM             TO
Commission file number: 001-37401
Community Healthcare Trust Incorporated
(Exact Name of Registrant as Specified in Its Charter)
Maryland
46-5212033
(State or Other Jurisdiction of Incorporation or Organization)
(I.R.S. Employer Identification No.)
3326 Aspen Grove Drive
Suite 150
Franklin, Tennessee 37067
(Address of Principal Executive Offices) (Zip Code)
(615) 771-3052
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class Trading Symbol Name of each exchange on which registered
Common stock, $0.01 par value per share CHCT New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ☒     No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  ☒     No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
 Accelerated filer
☐
Emerging-growth company
☐
Non-accelerated filer
☐
Smaller reporting 
company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 
Yes  ☐     No ☒
The Registrant had 27,264,446 shares of Common Stock, $0.01 par value per share, outstanding as of October 25, 2023.
1

COMMUNITY HEALTHCARE TRUST INCORPORATED
FORM 10-Q
September 30, 2023
TABLE OF CONTENTS
Page
    
2

PART I. FINANCIAL INFORMATION
ITEM 1.    FINANCIAL STATEMENTS
COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars and shares in thousands, except per share amounts)
(Unaudited)
September 30, 2023 December 31, 2022
ASSETS
Real estate properties
Land and land improvements
 $ 135,809  $ 117,657 
Buildings, improvements, and lease intangibles
 908,788  825,257 
Personal property
 296  253 
Total real estate properties
 1,044,893  943,167 
Less accumulated depreciation
 (192,962) (165,341)
Total real estate properties, net
 851,931  777,826 
Cash and cash equivalents
 3,885  11,233 
Restricted cash
 1,048  835 
Other assets, net
 98,262  86,531 
Total assets
 $ 955,126  $ 876,425 
LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities
Debt, net
 $ 401,192  $ 352,997 
Accounts payable and accrued liabilities
 15,446  11,377 
Other liabilities, net
 16,194  15,237 
Total liabilities
 432,832  379,611 
Commitments and contingencies


Stockholders' Equity
Preferred stock, $0.01 par value; 50,000 shares authorized; none issued and outstanding
 —  — 
Common stock, $0.01 par value; 450,000 shares authorized; 27,265 and 25,897 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
273  259 
Additional paid-in capital
 676,716  625,136 
Cumulative net income
 84,289  81,142 
Accumulated other comprehensive income
 29,038  22,667 
Cumulative dividends
 (268,022) (232,390)
Total stockholders’ equity
 522,294  496,814 
Total liabilities and stockholders' equity
 $ 955,126  $ 876,425 

See accompanying notes to the condensed consolidated financial statements.
3

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022
(Unaudited; Dollars and shares in thousands, except per share amounts)
Three Months Ended
September 30,		 Nine Months Ended
September 30,
2023 2022 2023 2022
REVENUES
Rental income
 $ 27,690  $ 23,919  $ 80,582  $ 69,720 
Other operating interest
 1,045  888  3,139  2,617 
28,735  24,807  83,721  72,337 
EXPENSES
Property operating
 5,456  4,327  15,115  12,480 
General and administrative (1)
 3,618  3,762  23,610  10,688 
Depreciation and amortization
 11,208  8,003  29,445  24,022 
20,282  16,092  68,170  47,190 
INCOME BEFORE INCOME TAXES AND OTHER ITEMS
 8,453  8,715  15,551  25,147 
Impairment of real estate asset
 (102) —  (102) — 
Interest expense
 (4,641) (3,028) (12,773) (8,409)
Deferred income tax expense
 (221) (21) (306) (20)
Interest and other income
 3  7  777  63 

3,492  5,673  3,147  16,781 
NET INCOME
 $ 3,492  $ 5,673  $ 3,147  $ 16,781 
NET INCOME PER COMMON SHARE:
Net income per common share – Basic
 $ 0.11  $ 0.21  $ 0.05  $ 0.62 
Net income per common share – Diluted
 $ 0.11  $ 0.21  $ 0.05  $ 0.62 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-BASIC
 25,514  23,587  24,940  23,578 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-DILUTED
 25,514  23,587  24,940  23,578 
___________
(1) General and administrative expenses for the nine months ended September 30, 2023 included stock-based compensation expense totaling approximately $17.9 million, including the accelerated amortization of stock-based compensation totaling approximately $11.8 million recognized upon the passing of our former CEO and President in the first quarter of 2023. General and administrative expenses for the nine months ended September 30, 2022 included stock-based compensation expense totaling approximately $6.8 million. See Note 9.

See accompanying notes to the condensed consolidated financial statements.










4




COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022
(Unaudited; Dollars in thousands)
Three Months Ended
September 30,		 Nine Months Ended
September 30,
2023 2022 2023 2022
NET INCOME
 $ 3,492  $ 5,673  $ 3,147  $ 16,781 
Other comprehensive income:
Increase in fair value of cash flow hedges
 8,691  8,983  13,593  24,974 
Reclassification for amounts recognized as interest expense
(2,738) (276) (7,222) 1,474 
Total other comprehensive income
 5,953  8,707  6,371  26,448 
COMPREHENSIVE INCOME
 $ 9,445  $ 14,380  $ 9,518  $ 43,229 

See accompanying notes to the condensed consolidated financial statements.

5

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023
(Unaudited; Dollars and shares in thousands, except per share amounts)
Preferred Stock
Common Stock
Additional Paid in Capital
Cumulative Net Income
Accumulated Other Comprehensive Income
Cumulative Dividends
Total Stockholders' Equity
Shares
Amount
Shares
Amount
Balance at June 30, 2023 —  $ —  26,541 $ 265  $ 657,057  $ 80,797  $ 23,085  $ (255,879) $ 505,325 
Issuance of common stock, net of issuance costs —  —  552 6  17,763  —  —  —  17,769 
Stock-based compensation, net of forfeitures —  —  172 2  1,896  —  —  —  1,898 
Increase in fair value of cash flow hedges —  —  — —  —  —  8,691  —  8,691 
Reclassification for amounts recognized as interest expense —  —  — —  —  —  (2,738) —  (2,738)
Net income —  —  — —  —  3,492  —  —  3,492 
Dividends to common stockholders ($0.4525 per share)
 —  —  — —  —  —  —  (12,143) (12,143)
Balance at September 30, 2023 —  $ —  27,265 $ 273  $ 676,716  $ 84,289  $ 29,038  $ (268,022) $ 522,294 
Balance at December 31, 2022 —  $ —  25,897 $ 259  $ 625,136  $ 81,142  $ 22,667  $ (232,390) $ 496,814 
Issuance of common stock, net of issuance costs —  —  1,037 11  34,610  —  —  —  34,621 
Stock-based compensation, net of forfeitures —  —  331 3  17,933  —  —  —  17,936 
Shares withheld on vesting of stock-based compensation —  —  —  —  (963) —  —  —  (963)
Increase in fair value of cash flow hedges —  —  — —  —  —  13,593  —  13,593 
Reclassification for amounts recognized as interest expense —  —  — —  —  —  (7,222) —  (7,222)
Net income —  —  — —  —  3,147  —  —  3,147 
Dividends to common stockholders ($1.3500 per share)
 —  —  — —  —  —  —  (35,632) (35,632)
Balance at September 30, 2023 —  $ —  27,265 $ 273  $ 676,716  $ 84,289  $ 29,038  $ (268,022) $ 522,294 


See accompanying notes to the condensed consolidated financial statements.
6

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022
(Unaudited; Dollars and shares in thousands, except per share amounts)
Preferred Stock
Common Stock
Additional Paid in Capital
Cumulative Net Income
Accumulated Other Comprehensive (Loss) Income
Cumulative Dividends
Total Stockholders' Equity
Shares
Amount
Shares
Amount
Balance at June 30, 2022 —  $ —  25,099 $ 251  $ 599,631  $ 70,231  $ 12,761  $ (209,912) $ 472,962 
Stock issuance costs —  —  — —  (125) —  —  —  (125)
Stock-based compensation, net of forfeitures —  —  200 2  2,462  —  —  —  2,464 
Increase in fair value of cash flow hedges —  —  — —  —  —  8,983  —  8,983 
Reclassification for amounts recognized as interest expense —  —  — —  —  —  (276) —  (276)
Net income —  —  — —  —  5,673  —  —  5,673 
Dividends to common stockholders ($0.4425 per share)
 —  —  — —  —  —  —  (11,195) (11,195)
Balance at September 30, 2022 —  $ —  25,299 $ 253  $ 601,968  $ 75,904  $ 21,468  $ (221,107) $ 478,486 
Balance at December 31, 2021 —  $ —  24,983 $ 250  $ 595,624  $ 59,123  $ (4,980) $ (187,905) $ 462,112 
Issuance of common stock —  —  — —  (423) —  —  —  (423)
Stock-based compensation, net of forfeitures —  —  316 3  6,767  —  —  —  6,770 
Increase in fair value of cash flow hedges —  —  — —  —  —  24,974  —  24,974 
Reclassification for amounts recognized as interest expense —  —  — —  —  —  1,474  —  1,474 
Net income —  —  — —  —  16,781  —  —  16,781 
Dividends to common stockholders ($1.3200 per share)
 —  —  — —  —  —  —  (33,202) (33,202)
Balance at September 30, 2022 —  $ —  25,299 $ 253  $ 601,968  $ 75,904  $ 21,468  $ (221,107) $ 478,486 


See accompanying notes to the condensed consolidated financial statements.
7

COMMUNITY HEALTHCARE TRUST INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; Dollars in thousands)
Nine Months Ended
September 30,
2023 2022
OPERATING ACTIVITIES
Net income
 $ 3,147  $ 16,781 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
 29,445  24,022 
Other amortization
 558  627 
Stock-based compensation
 6,137  6,770 
Accelerated amortization of stock-based compensation 11,799  — 
Straight-line rent receivable
 (2,180) (2,590)
Net gain from insurance recovery on casualty loss (706) — 
Impairment of real estate asset
 102  — 
Deferred income tax expense
 306  20 
Changes in operating assets and liabilities:
Other assets
 (3,082) (1,367)
Accounts payable and accrued liabilities
 3,337  994 
Other liabilities
 (1,772) (387)
Net cash provided by operating activities
 47,091  44,870 
INVESTING ACTIVITIES
Acquisitions of real estate
 (91,993) (45,970)
        Funding of notes receivable
 (1,985) (5,500)
Proceeds from the repayment of notes receivable
 3,045  2,250 
Insurance proceeds from casualty loss 2,273  — 
Capital expenditures on existing real estate properties
 (11,461) (6,698)
Net cash used in investing activities
 (100,121) (55,918)
FINANCING ACTIVITIES
Net borrowings on revolving credit facility
 48,000  45,000 
Mortgage note repayments
 (94) (98)
Dividends paid
 (35,632) (33,202)
Proceeds from issuance of common stock
 34,766  — 
Taxes paid on behalf of employees and shares withheld upon shares vesting (963) — 
Equity issuance costs
 (182) (181)
Net cash provided by financing activities
 45,895  11,519 
(Decrease) increase in cash and cash equivalents and restricted cash
 (7,135) 471 
Cash and cash equivalents and restricted cash, beginning of period
 12,068  2,867 
Cash and cash equivalents and restricted cash, end of period
 $ 4,933  $ 3,338 
Supplemental Cash Flow Information:
Interest paid (net of capitalized interest)
 $ 9,868  $ 7,525 
Invoices accrued for construction, tenant improvement and other capitalized costs
 $ 4,922  $ 1,588 
Reclassification of registration statement costs incurred in prior years to equity issuance costs
 $ 145  $ 344 
Leasing commission accrued
 $ 449  $ — 
Increase in fair value of cash flow hedges
 $ 13,593  $ 24,974 
Income taxes paid
 $ 90  $ 65 
Capitalized interest $ 514  $ 504 
See accompanying notes to the condensed consolidated financial statements.
8

COMMUNITY HEALTHCARE TRUST INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023
(Unaudited)

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Business Overview
Community Healthcare Trust Incorporated (the ‘‘Company’’, ‘‘we’’, ‘‘our’’) was organized in the State of Maryland on March 28, 2014. The Company is a fully-integrated healthcare real estate company that owns and acquires real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers. As of September 30, 2023, the Company had investments of approximately $1.05 billion in 191 real estate properties (including a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million and one property classified as an asset held for sale with a gross amount totaling approximately $1.1 million (see Note 10 – Other Assets, net and Note 4 – Real Estate Acquisitions and Dispositions, respectively)). The properties are located in 34 states, totaling approximately 4.2 million square feet in the aggregate and were approximately 91.0% leased at September 30, 2023 with a weighted average remaining lease term of approximately 7.1 years. Any references to square footage, property count, or occupancy percentages, and any amounts derived from these values in these notes to the Condensed Consolidated Financial Statements, are outside the scope of our independent registered public accounting firm's review.

Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. This interim financial information should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. This interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2023. All intercompany accounts and transactions have been eliminated.

Use of Estimates in the Condensed Consolidated Financial Statements
Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may materially differ from those estimates.

Cash and Cash Equivalents and Restricted Cash
Cash and cash equivalents includes short-term investments with original maturities of three months or less when purchased. Restricted cash consists of amounts held by the lender of our mortgage note payable to provide for future real estate tax, insurance expenditures and tenant improvements related to one property. The carrying amounts approximate fair value due to the short term maturity of these investments. The following table provides a reconciliation of cash and cash equivalents and restricted cash:
 Balance as of September 30,
(Dollars in thousands) 2023 2022
Cash and cash equivalents $ 3,885  $ 2,656 
Restricted cash 1,048  682 
Cash, cash equivalents and restricted cash $ 4,933  $ 3,338 

Income Taxes
The Company has elected to be taxed as a real estate investment trust ("REIT"), as defined under the Internal Revenue Code of 1986, as amended (the "Code"). The Company and two subsidiaries have also elected for those subsidiaries to be treated as taxable REIT subsidiaries ("TRSs"), which are subject to federal and state income taxes.
9
Notes to Condensed Consolidated Financial Statements - Continued
No provision has been made for federal income taxes for the REIT; however, the Company has recorded income tax expense or benefit for the TRSs to the extent applicable. The Company also evaluates the realizability of its deferred tax assets and will record valuation allowances if it is determined that more likely than not the asset will not be recovered. The Company intends at all times to qualify as a REIT under the Code. The Company must distribute at least 90% per annum of its REIT taxable income to its stockholders (which is computed without regard to the dividends paid deduction or net capital gain and which does not necessarily equal net income as calculated in accordance with GAAP) and meet other requirements to continue to qualify as a REIT.

NOTE 2. REAL ESTATE PROPERTIES

As of September 30, 2023, we had investments of approximately $1.05 billion in 191 real estate properties (including a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million and one property classified as held for sale with a gross amount totaling approximately $1.1 million). The Company's investments are diversified by property type, geographic location, and tenant as shown in the following tables:
Property Type # of Properties Gross Investment
(in thousands)
Medical Office Building 91  $ 424,174 
Inpatient Rehabilitation Hospitals 8  174,772 
Acute Inpatient Behavioral 5  130,472 
Specialty Centers 37  120,095 
Physician Clinics 30  86,735 
Surgical Centers and Hospitals 10  52,823 
Behavioral Specialty Facilities 9  45,017 
Long-term Acute Care Hospitals 1  14,937 
Total 191  $ 1,049,025 

State # of Properties Gross Investment
(in thousands)
Texas 17  $ 162,455 
Illinois 16  122,384 
Ohio 26  113,086 
Florida 25  109,846 
Pennsylvania 15  57,568 
All Others 92  483,686 
Total 191  $ 1,049,025 

Primary Tenant # of Properties Gross Investment
(in thousands)
Lifepoint Health (1)
 6  $ 105,888 
US HealthVest 3  77,964 
All Others 182  865,173 
Total 191  $ 1,049,025 
____________
(1) During the first quarter of 2023, Everest Rehabilitation assigned leases on four properties to Lifepoint Health in which the Company had a gross investment totaling $80.7 million at September 30, 2023.

10
Notes to Condensed Consolidated Financial Statements - Continued
GenesisCare Bankruptcy
On June 1, 2023, GenesisCare and certain of its affiliates ("GenesisCare") filed voluntary petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code. During the second quarter of 2023, the U.S. Bankruptcy Court for the Southern District of Texas approved GenesisCare’s request to reject a lease of approximately 11,000 square feet with CHCT North Carolina, LLC, a subsidiary of the Company and during the third quarter of 2023, GenesisCare's request to reject an additional unexpired real property lease of approximately 46,000 square feet with CHCT Florida, LLC, a subsidiary of the Company, was approved.

At September 30, 2023, GenesisCare was the sole tenant in five of our properties and a tenant in two of our multi-tenanted properties, representing approximately 1.9% of our gross real estate properties, or approximately 62,000 square feet. Other than the two rejected leases noted above, GenesisCare has met substantially all of its lease payment obligations due to the Company through October 2023. The Company has engaged counsel to monitor the GenesisCare bankruptcy progress and any additional potential impacts to the Company.

NOTE 3. REAL ESTATE LEASES

Lessor Accounting
The Company’s properties are generally leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2039. The Company’s leases generally require the lessee to pay minimum rent, with fixed rent renewal terms or increases based on a Consumer Price Index and may also include additional rent, which may include the reimbursement of taxes (including property taxes), insurance, maintenance and other operating costs associated with the leased property.

Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. Some leases also allow the lessee to renew or extend their lease term or in some cases terminate their lease, based on conditions provided in the lease.

Future minimum lease payments under the non-cancelable operating leases due to the Company for the years ending December 31, as of September 30, 2023, are as follows (in thousands):
2023 (three months ended December 31) $ 24,203 
2024 93,601 
2025 85,888 
2026 76,764 
2027 69,814 
2028 and thereafter 404,637 
$ 754,907 

Rental income is recognized as earned over the life of the lease agreement on a straight-line basis when collection of rental payments over the term of the lease is probable. Straight-line rent included in rental income was approximately $0.4 million and $0.9 million, respectively, for the three months ended September 30, 2023 and 2022, and was approximately $2.2 million and $2.6 million, respectively, for the nine months ended September 30, 2023 and 2022.

Purchase Option Provisions
Certain of the Company's leases provide the lessee with a purchase option or a right of first refusal to purchase the leased property. The purchase option provisions generally allow the lessee to purchase the leased property at fair value or at an amount greater than the Company's gross investment in the leased property at the time of the purchase. At September 30, 2023, the Company had an aggregate gross investment of approximately $40.4 million in 11 real estate properties with purchase options exercisable at September 30, 2023 that had not been exercised.

11
Notes to Condensed Consolidated Financial Statements - Continued
Sales-type Lease
The Company has a portion of one property accounted for as a sales-type lease with a gross amount totaling approximately $3.0 million included in other assets, net on the Company's Condensed Consolidated Balance Sheets. Future lease payments due to the Company under this lease for the years ending December 31, as of September 30, 2023, are as follows (in thousands):

2023 (three months ended December 31) $ 85 
2024 346 
2025 356 
2026 367 
2027 378 
2028 and thereafter 5,210 
Total undiscounted lease receivable 6,742 
Discount (3,710)
Lease receivable $ 3,032 

The Company recognized interest income of approximately $0.1 million during each of the three months ended September 30, 2023 and 2022 and approximately $0.2 million during each of the nine months ended September 30, 2023 and 2022 related to this lease which is included in other operating interest on the Company's Condensed Consolidated Statements of Income.

Lessee Accounting
At September 30, 2023, the Company was obligated, as the lessee, under four non-prepaid ground leases accounted for as operating leases with expiration dates, including renewal options, through 2076, and two non-prepaid ground leases accounted for as financing leases with expiration dates through 2109, including renewal options. Any rental increases related to the Company's ground leases are generally either stated or based on the Consumer Price Index. The Company's future lease payments under these non-prepaid ground leases were as follows (in thousands):

Operating Financing
2023 (three months ended December 31) $ 11  $ 35 
2024 43  154 
2025 44  154 
2026 44  154 
2027 45  154 
2028 and thereafter 1,148  6,956 
Total undiscounted lease payments 1,335  7,607 
Discount (558) (4,330)
Lease liabilities $ 777  $ 3,277 

The following table discloses other information regarding the ground leases.
Three Months Ended
September 30,
2023 2022
Operating leases:
Weighted-average remaining lease term in years (including renewal options) 35.4 36.1
Weighted-average discount rate 4.0  % 4.0  %
Financing leases:
Weighted-average remaining lease term in years (including renewal options) 40.1 41.0
Weighted-average discount rate 4.3  % 4.2  %
12
Notes to Condensed Consolidated Financial Statements - Continued
NOTE 4. REAL ESTATE ACQUISITIONS AND DISPOSITIONS

Acquisitions
During the third quarter of 2023, the Company acquired seven real estate properties. Upon acquisition, the properties were 99.8% leased in the aggregate with lease expirations through 2038. Amounts reflected in revenues and net income for these properties for the three months ended September 30, 2023 were approximately $0.8 million and $0.4 million, respectively, and transaction costs totaling approximately $0.7 million were capitalized relating to these property acquisitions.

During the second quarter of 2023, the Company acquired three real estate properties and one land parcel. Upon acquisition, the properties were 98.3% leased in the aggregate with lease expirations through 2033. Amounts reflected in revenues and net income for these properties for the nine months ended September 30, 2023 were approximately $0.6 million and $0.1 million, respectively, and transaction costs totaling approximately $0.4 million were capitalized relating to these property acquisitions.

During the first quarter of 2023, the Company acquired seven real estate properties. Upon acquisition, the properties were 100.0% leased in the aggregate with lease expirations through 2031. Amounts reflected in revenues and net income for these properties for the nine months ended September 30, 2023 were approximately $2.2 million and $0.5 million, respectively, and transaction costs totaling approximately $0.4 million were capitalized relating to these property acquisitions.

The following table summarizes our property acquisitions for the nine months ended September 30, 2023:
Location
Property
Type (1)
 Date
Acquired		 Purchase
Price		 Cash
Consideration		 Real Estate
Other (2)
 Square Footage
(000's) (000's) (000's) (000's)
LaGrange, GA MOB 01/18/23 $ 8,007  $ 8,087  $ 8,118  $ (31) 55,310 
West Point, GA MOB 01/18/23 811  819  822  (3) 5,600 
Canton, OH MOB 01/30/23 3,669  3,706  4,287  (581) 27,920 
Scranton, PA MOB 02/23/23 1,957  2,165  2,317  (152) 22,743 
Scranton, PA MOB 02/23/23 2,207  2,366  2,340  26  15,768 
LaGrange, GA MOB 03/06/23 6,469  6,458  6,622  (164) 31,473 
LaGrange, GA MOB 03/06/23 249  294  300  (6) 2,972 
Lakeland, FL Land 04/03/23 838  845  846  (1) — 
Hermitage, PA MOB 05/04/23 4,218  4,382  4,529  (147) 25,982 
San Antonio, TX MOB 05/22/23 2,772  2,783  3,031  (248) 12,376 
Clinton, MD MOB 06/21/23 7,850  7,807  7,867  (60) 37,344 
Ft. Myers, FL MOB 07/28/23 10,646  10,739  10,952  (213) 43,322 
Ft. Myers, FL MOB 07/28/23 582  588  497  91  3,200 
Immokalee, FL MOB 07/28/23 847  863  881  (18) 6,757 
El Paso, TX IRF 07/31/23 23,500  23,538  23,538  —  37,992 
Beaver, PA MOB 08/24/23 3,330  3,496  3,581  (85) 15,878 
Westlake, OH MOB 08/25/23 2,425  2,444  2,535  (91) 14,100 
Newcastle, PA MOB 09/15/23 10,375  10,613  11,239  (626) 56,003 
$ 90,752  $ 91,993  $ 94,302  $ (2,309) 414,740 
(1) MOB - Medical Office Building; IRF - Inpatient Rehabilitation Facility
(2) Includes other assets acquired, liabilities assumed, and above and below-market intangibles recognized at acquisition.



13
Notes to Condensed Consolidated Financial Statements - Continued
The following table summarizes the relative fair values of the assets acquired and liabilities assumed in the property acquisitions for the nine months ended September 30, 2023:
Relative
Fair Value		 Estimated
Useful Life
(in thousands) (in years)
Land and land improvements $ 17,836  8.7
Building and building improvements 65,765  30.8
Intangibles:
At-market lease intangibles 10,701  4.5
Above-market lease intangibles 976  5.1
Below-market lease intangibles (2,940) 5.4
Total intangibles 8,737 
Accounts payable, accrued liabilities and other liabilities assumed (399)
Accounts receivable and other assets acquired 303 
Prorated rent, interest and operating expense reimbursement amounts collected (249)
Total cash consideration $ 91,993 

Asset Held for Sale
The Company incurred property damage due to vandalism at a property in Houston, Texas which was covered by our insurance policies. The Company estimated the fair value of the damaged property and recorded a casualty loss, for the difference between the estimated fair value less costs to sell and the insurance proceeds received. The Company determined that the estimated amount of the casualty loss was approximately $1.6 million and received insurance proceeds totaling $2.3 million in the second quarter of 2023, resulting in a net casualty gain of approximately $0.7 million which was included in Interest and other income on the Condensed Consolidated Statements of Income.

At June 30, 2023, the Company committed to a plan to dispose of the property in Houston, Texas and classified the property as an asset held for sale. The Company recorded an impairment on the asset held for sale of approximately $0.1 million in the third quarter of 2023. See also Note 10 – Other Assets, net and Note 11 – Other Liabilities, net.


NOTE 5. DEBT, NET

The table below details the Company's debt as of September 30, 2023 and December 31, 2022.
Balance as of
(Dollars in thousands) September 30, 2023 December 31, 2022 Maturity Dates
Credit Facility:
Revolving Credit Facility $ 48,000  $ —  3/26
A-3 Term Loan, net 74,700  74,609  3/26
A-4 Term Loan, net 124,494  124,409  3/28
A-5 Term Loan, net 149,157  149,059  3/30
Mortgage Note Payable, net 4,841  4,920  5/24
$ 401,192  $ 352,997 

On December 14, 2022, Community Healthcare Trust Incorporated, as borrower, entered into a first amendment (the "First Amendment") to the third amended and restated credit agreement (the "Credit Facility") by and among Community Healthcare Trust Incorporated, as borrower, the several banks and financial institutions party thereto as lenders, and Truist Bank, as administrative agent.
14
Notes to Condensed Consolidated Financial Statements - Continued
The First Amendment amended the Credit Facility to, among other things, (i) establish a new seven-year and three-month term loan facility in the aggregate principal amount of $150.0 million (the "A-5 Term Loan"), which matures on March 14, 2030 and (ii) replace LIBOR as a benchmark interest rate for loans under the Credit Facility with SOFR. The proceeds from the A-5 Term Loan were used in part to repay the seven-year term loan facility in the aggregate principal amount of $50.0 million (the "A-2 Term Loan") which was set to mature on March 29, 2024.

The Credit Facility allows the Company to borrow, through the accordion feature, up to $700.0 million, including the ability to add and fund incremental term loans. The Company's material subsidiaries are guarantors of the obligations under the Credit Facility.

The Credit Facility provides for a $150.0 million Revolving Credit Facility and $350.0 million in term loans (the "Term Loans"). The Revolving Credit Facility matures on March 19, 2026 and includes one 12-month option to extend the maturity date, subject to the satisfaction of certain conditions. The Term Loans include a seven-year term loan facility in the aggregate principal amount of $75.0 million (the "A-3 Term Loan"), which matures on March 29, 2026, a seven-year term loan facility in the aggregate principal amount of $125.0 million (the "A-4 Term Loan"), which matures on March 19, 2028, and the A-5 Term Loan, which matures on March 14, 2030.

Under the First Amendment, amounts outstanding under the Revolving Credit Facility will bear interest at a floating rate based on the Company's option, on either: (i) adjusted term SOFR or adjusted daily simple SOFR plus 1.25% to 1.90% or (ii) a base rate plus 0.25% to 0.90% in each case, depending upon the Company’s leverage ratio. In addition, the Company is obligated to pay an annual fee equal to 0.20% of the amount of the unused portion of the Revolving Credit Facility if amounts borrowed are greater than 33.3% of the borrowing capacity under the Revolving Credit Facility and 0.25% of the unused portion of the Revolving Credit Facility if amounts borrowed are less than or equal to 33.3% of the borrowing capacity under the Revolving Credit Facility. The Company had $48.0 million outstanding under the Revolving Credit Facility with a weighted average interest rate of 7.05% and a borrowing capacity remaining of $102.0 million at September 30, 2023.

Under the First Amendment, amounts outstanding under the Term Loans will bear interest at a floating rate that is based, at the Company's option, on either (i) adjusted term SOFR or adjusted daily SOFR plus 1.45% to 2.30% or (ii) a base rate plus 0.45% to 1.30%, in each case, depending upon the Company’s leverage ratio. The Company has entered into interest rate swaps to fix the interest rates on the Term Loans. See Note 6 – Derivative Financial Instruments for more details on the interest rate swaps. At September 30, 2023, the Company had $350.0 million outstanding under the Term Loans which had a fixed weighted average interest rate under the swaps of approximately 4.3%.

The Company’s ability to borrow under the Credit Facility is subject to its ongoing compliance with a number of customary affirmative and negative covenants, including limitations with respect to liens, indebtedness, distributions, mergers, consolidations, investments, restricted payments and asset sales, as well as financial maintenance covenants. The Company was in compliance with its financial covenants under its Credit Facility as of September 30, 2023.

Mortgage Note Payable
The Company's mortgage note payable is secured by a building which had a $6.8 million carrying balance at September 30, 2023. The mortgage note amortizes monthly at a fixed interest rate of 4.98% with a balloon payment of approximately $4.8 million due upon maturity on May 1, 2024.

NOTE 6. DERIVATIVE FINANCIAL INSTRUMENTS

Risk Management Objective of Using Derivatives
The Company may use derivative financial instruments, including interest rate swaps, caps, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings. The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions. The Company does not intend to utilize derivatives for speculative or other purposes other than interest rate risk management.
15
Notes to Condensed Consolidated Financial Statements - Continued
The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company and its affiliates may also have other financial relationships. The Company does not anticipate that any of the counterparties will fail to meet their obligations.

Cash Flow Hedges of Interest Rate Risk
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount.

As of September 30, 2023, the Company had seventeen outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk for notional amounts totaling $350.0 million, including two forward-starting interest rate swaps for notional amounts totaling $50.0 million, which will not become effective until March 29, 2024.

Tabular Disclosure of Fair Value of Derivative Instruments on the Balance Sheet
The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022.
Asset Derivatives Fair Value at Liability Derivatives Fair Value at
(Dollars in thousands) September 30, 2023 December 31, 2022 Balance Sheet Classification September 30, 2023 December 31, 2022 Balance Sheet Classification
Interest rate swaps $ 29,038  $ 22,667  Other assets, net $ —  $ —  Other liabilities, net

The changes in the fair value of derivatives designated and that qualify as cash flow hedges are recorded in accumulated other comprehensive income ("AOCI") and are subsequently reclassified to interest expense in the period that the hedged forecasted transaction affects earnings.

Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s Term Loans. During the next twelve months, the Company estimates that an additional $10.7 million will be reclassified from AOCI as a decrease to interest expense.

Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income
The table below details the location in the financial statements of the gain or loss recognized on interest rate derivatives designated as cash flow hedges for the three and nine months ended September 30, 2023 and 2022.
Three Months Ended
September 30,		 Nine Months Ended
September 30,
(Dollars in thousands) 2023 2022 2023 2022
Amount of unrealized gain recognized in OCI on derivatives $ 8,691  $ 8,983  $ 13,593  $ 24,974 
Amount of (gain) loss reclassified from AOCI into interest expense $ (2,738) $ (276) $ (7,222) $ 1,474 
Total interest expense presented in the Condensed Consolidated Statements of Income in which the effects of the cash flow hedges are recorded $ 4,641  $ 3,028  $ 12,773  $ 8,409 




16
Notes to Condensed Consolidated Financial Statements - Continued
Tabular Disclosures of Offsetting Derivatives
The tables below present a gross presentation, the effects of offsetting, and a net presentation of the Company's derivatives as of September 30, 2023 and December 31, 2022. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the Condensed Consolidated Balance Sheets.
Offsetting of Derivative Assets (as of September 30, 2023)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands) Gross Amounts of Recognized Assets Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Assets in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount
Derivatives $ 29,038  $ —  $ 29,038  $ —  $ —  $ 29,038 

Offsetting of Derivative Liabilities (as of September 30, 2023)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands) Gross Amounts of Recognized Liabilities Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Liabilities in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount
Derivatives $ —  $ —  $ —  $ —  $ —  $ — 

Offsetting of Derivative Assets (as of December 31, 2022)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands) Gross Amounts of Recognized Assets Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Assets in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount
Derivatives $ 22,667  $ —  $ 22,667  $ —  $ —  $ 22,667 

Offsetting of Derivative Liabilities (as of December 31, 2022)
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
(In thousands) Gross Amounts of Recognized Liabilities Gross Amounts Offset in the Condensed Consolidated Balance Sheet Net Amounts of Liabilities in the Condensed Consolidated Balance Sheets Financial Instruments Cash Collateral Received Net Amount
Derivatives $ —  $ —  $ —  $ —  $ —  $ — 

Credit-risk-related Contingent Features
As of September 30, 2023, the Company did not have any derivatives in a net liability position. As of September 30, 2023, the Company had not posted any collateral related to these agreements and was not in breach of any agreement provisions. If the Company terminated these interest rate swaps or breached any of these provisions, it could have been required to settle its obligations under the agreements at their aggregate termination value.





17
Notes to Condensed Consolidated Financial Statements - Continued
NOTE 7. STOCKHOLDERS' EQUITY

Common Stock
The following table provides a reconciliation of the beginning and ending common stock balances for the nine months ended September 30, 2023 and for the year ended December 31, 2022:
(In thousands) Nine Months Ended
September 30, 2023		 Year Ended
December 31, 2022
Balance, beginning of period 25,897 24,983
Issuance of common stock
 1,037 600
Restricted stock issued 361 318
Restricted stock withheld and forfeited (30) (4)
Balance, end of period 27,265 25,897
ATM Program
The Company has an at-the-market offering program ("ATM Program"), with Piper Sandler & Co., Evercore Group L.L.C., Truist Securities, Inc., Regions Securities LLC, Robert W. Baird & Co. Incorporated, Fifth Third Securities, Inc. and Janney Montgomery Scott LLC, as sales agents (collectively, the “Agents”). Under the ATM Program, the Company may issue and sell shares of its common stock, having an aggregate gross sales price of up to $500.0 million. The shares of common stock may be sold from time to time through or to one or more of the Agents, as may be determined by the Company in its sole discretion, subject to the terms and conditions of the agreement and applicable law.

The Company's activity under the ATM Program during the nine months ended September 30, 2023 is detailed in the table below. As of September 30, 2023, the Company had approximately $443.6 million remaining that may be issued under the ATM Program.

Three Months Ended
September 30, 2023		 Nine Months Ended
September 30, 2023
Shares issued (in thousands)
 552 1,037
Net proceeds received (in millions)
 $17.8 $34.8
Average gross sales price per share $32.93 $34.18


18
Notes to Condensed Consolidated Financial Statements - Continued
NOTE 8. NET INCOME PER COMMON SHARE

The following table sets forth the computation of basic and diluted net income per common share for the three and nine months ended September 30, 2023 and 2022, respectively.

 Three Months Ended
September 30,		 Nine Months Ended
September 30,
(In thousands, except per share data) 2023 2022 2023 2022
Net income $ 3,492  $ 5,673  $ 3,147  $ 16,781 
          Participating securities' share in earnings (622) (759) (1,995) (2,086)
Net income, less participating securities' share in earnings $ 2,870  $ 4,914  $ 1,152  $ 14,695 
Weighted average Common Shares outstanding
Weighted average Common Shares outstanding
 26,823  25,221  26,411  25,123 
Unvested restricted shares
 (1,309) (1,634) (1,471) (1,545)
Weighted average Common Shares outstanding–Basic
 25,514  23,587  24,940  23,578 
Dilutive potential common shares
 —  —  —  — 
Weighted average Common Shares outstanding –Diluted
 25,514  23,587  24,940  23,578 
Basic Net Income per Common Share $ 0.11  $ 0.21  $ 0.05  $ 0.62 
Diluted Net Income per Common Share $ 0.11  $ 0.21  $ 0.05  $ 0.62 

NOTE 9. STOCK INCENTIVE PLAN

A summary of the activity under the Company's 2014 Incentive Plan, as amended, for the three and nine months ended September 30, 2023 and 2022 is included in the table below, as well as compensation expense recognized from the amortization of the value of shares over the applicable vesting periods.
Three Months Ended
September 30,		 Nine Months Ended
September 30,
(Dollars and shares in thousands) 2023 2022 2023 2022
Stock-based awards, beginning of period 1,203  1,512  1,708  1,416 
Stock in lieu of compensation 57  64  141  116 
Stock awards 114  136  220  203 
   Total stock granted 171  200  361  319 
Vested shares (1)
 —  —  (692) (22)
Forfeited shares —  —  (3) (1)
Stock-based awards, end of period 1,374  1,712  1,374  1,712 
Amortization expense (1)
 $ 1,898  $ 2,464  $ 17,936  $ 6,770 
___________
(1) Amortization expense for the nine months ended September 30, 2023 included accelerated amortization totaling approximately $11.8 million and vesting of 624,725 shares upon the passing of our former CEO and President.

Accelerated Amortization and Vesting of Restricted Stock
The Company's former CEO and President, Timothy Wallace, passed away in March 2023. At the time of his passing, Mr. Wallace had 624,725 shares of restricted stock that had not been fully amortized. In accordance with the terms of his employment agreement, the Company accelerated the unamortized remaining balance of deferred compensation related to his unvested shares and recognized an additional $11.8 million of amortization expense in the first quarter of 2023.

19
Notes to Condensed Consolidated Financial Statements - Continued

NOTE 10. OTHER ASSETS, NET

Other assets, net on the Company's Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 are detailed in the table below.
Balance as of
(Dollars in thousands) September 30, 2023 December 31, 2022
Notes receivable $ 31,645  $ 32,705 
Accounts and interest receivable, net 4,053  2,679 
Straight-line rent receivable 17,899  15,429 
Prepaid assets 1,802  980 
Deferred financing costs, net 524  683 
Leasing commissions, net 2,409  1,848 
Deferred tax assets, net —  306 
Fair value of interest rate swaps 29,038  22,667 
Above-market lease intangible assets, net 2,853  2,399 
Sales-type lease receivable 3,032  3,035 
Financing right-of-use asset 2,501  2,545 
Assets held for sale 1,116  — 
Operating lease right-of-use assets 735  759 
Other 655  496 
$ 98,262  $ 86,531 

The Company's notes receivable mainly included:

•At September 30, 2023 and December 31, 2022, notes receivable included a $6.8 million and $9.0 million, respectively, term loan, secured by all assets and ownership interests in seven long-term acute care hospitals and one inpatient rehabilitation hospital owned by the borrower. The term loan will be repaid in equal monthly installments of $250,000 through the maturity date of December 31, 2025 and bears interest at 9% per annum.

•At September 30, 2023 and December 31, 2022, notes receivable included a term loan totaling $17.0 million and a revolving credit facility totaling $5.4 million and $5.0 million, respectively, secured by assets and ownership interests of six geriatric behavioral hospitals and affiliated companies all of which are co-borrowers on the loans. The term loan bears interest at 9% per annum, with interest only payments due initially and then equal monthly installments of principal payments due beginning March 31, 2024. The term loan facility matures on December 31, 2032. The revolving credit facility bears interest at 9% per annum and matures on December 31, 2025. In addition, the Company has committed to fund, at the Company’s discretion, additional amounts, up to $5.0 million with interest at 9% per annum on any amount funded, that may be used by the borrower to pay existing liabilities of co-borrowers. The term loan, the revolving credit facility and the additional commitment all include a 3% per annum non-cash interest charge that is due and payable upon the earlier of the repayment or maturity of each note.

•At September 30, 2023 and December 31, 2022, notes receivable included a $2.5 million and $1.7 million, respectively, revolving credit facility. Commencing on October 1, 2023, the revolving credit facility will be repaid in equal monthly installments of $40,000 through the maturity date of April 1, 2027. The revolving credit facility bears interest at 9% per annum, as well as a 3% per annum non-cash interest charge that is due and payable upon the earlier of the repayment or maturity of the note.

The Company identified the borrowers of these notes as variable interest entities ("VIEs"), but management determined that the Company was not the primary beneficiary of the VIEs because we lack either directly or through related parties any material decision-making rights or control of the entities that impact the borrowers' economic performance.
20
Notes to Condensed Consolidated Financial Statements - Continued
We are not obligated to provide support beyond our stated commitment to the borrowers, and accordingly our maximum exposure to loss as a result of this relationship is limited to the amount of our outstanding notes receivable. The VIEs that we have identified at September 30, 2023 are summarized in the table below.
Classification
Carrying Amount
(in thousands)
Maximum Exposure to Loss
(in thousands)
Note receivable (term loan) $ 6,750  $ 6,750 
Note receivable (revolving credit facility) $ 5,435  $ 5,435 
Note receivable (term loan) $ 17,000  $ 17,000 
Note receivable (revolving credit facility) $ 2,460  $ 2,460 

NOTE 11. OTHER LIABILITIES, NET

Other liabilities, net on the Company's Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 are detailed in the table below.
Balance as of
(Dollars in thousands) September 30, 2023 December 31, 2022
Prepaid rent $ 4,699  $ 3,853 
Security deposits 3,676  5,766 
Below-market lease intangibles, net 3,261  1,075 
Financing lease liability 3,277  3,279 
Operating lease liability 777  786 
Liabilities held for sale 48  — 
Other 456  478 
$ 16,194  $ 15,237 

NOTE 12. FAIR VALUE OF FINANCIAL INSTRUMENTS

The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practical to estimate the fair value.

Cash and cash equivalents and restricted cash - The carrying amount approximates the fair value. The fair value estimates were determined using level 1 inputs.

Notes receivable - The fair value is estimated using cash flow analyses, based on an assumed market rate of interest or at a rate consistent with the rates on notes carried by the Company and are classified as level 2 inputs in the hierarchy.

Borrowings under our Credit Facility - The carrying amount approximates the fair value because the borrowings are based on variable market interest rates. The fair value estimates were determined using level 2 inputs.

Derivative financial instruments (Interest rate swaps) - The fair value is estimated using discounted cash flow techniques. These techniques incorporate primarily level 2 inputs. The market inputs are utilized in the discounted cash flow calculation considering the instrument’s term, notional amount, discount rate and credit risk. Significant inputs to the derivative valuation model for interest rate swaps are observable in active markets and are classified as level 2 inputs in the hierarchy.

Mortgage note payable - The fair value is estimated using cash flow analyses which are based on an assumed market rate of interest or at a rate consistent with the rates on mortgage notes assumed by the Company and are classified as level 2 inputs in the hierarchy.

21
Notes to Condensed Consolidated Financial Statements - Continued
The table below details the fair values and carrying values for our notes receivable, interest rate swaps, and mortgage note payable at September 30, 2023 and December 31, 2022, using level 2 inputs.
September 30, 2023 December 31, 2022
(Dollars in thousands) Carrying Value Fair Value Carrying Value Fair Value
Notes receivable $ 31,645  $ 31,321  $ 32,705  $ 32,716 
Interest rate swap asset $ 29,038  $ 29,038  $ 22,667  $ 22,667 
Mortgage note payable (principal amount) $ 4,853  $ 4,731  $ 4,947  $ 4,761 

NOTE 13. SUBSEQUENT EVENTS

Dividend Declared
On October 26, 2023, the Company’s Board of Directors declared a quarterly common stock dividend in the amount of $0.455 per share. The dividend is payable on November 24, 2023 to stockholders of record on November 9, 2023.

Subsequent Acquisitions
Subsequent to September 30, 2023, the Company acquired two medical office buildings in a single transaction for an aggregate purchase price and cash consideration of approximately $7.1 million. Upon acquisition, the properties were 96.8% leased in the aggregate with lease expirations through 2031.


22

ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Disclosure Regarding Forward-Looking Statements
This report and other materials that Community Healthcare Trust Incorporated (the "Company") has filed or may file with the Securities and Exchange Commission, as well as information included in oral statements or other written statements made, or to be made, by management of the Company, contain, or will contain, statements that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identifiable by use of forward-looking terminology such as “believes”, “expects”, “may”, "will', “should”, “seeks”, “approximately”, “intends”, “plans”, “estimates”, “anticipates” or other similar words or expressions, including the negative thereof. Forward-looking statements are based on certain assumptions and can include future expectations, future plans and strategies, financial and operating projections or other forward-looking information. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. Because forward-looking statements relate to future events, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Thus, the Company’s actual results and financial condition may differ materially from those indicated in such forward-looking statements. Some factors that might cause such a difference include the following: general volatility of the capital markets and the market price of the Company’s common stock, changes in the Company’s business strategy, availability, terms and deployment of capital, the Company’s ability to refinance existing indebtedness at or prior to maturity on favorable terms, or at all, changes in the real estate industry in general, interest rates or the general economy, adverse developments related to the healthcare industry, changes in governmental regulations, the degree and nature of the Company’s competition, the ability to consummate acquisitions under contract, catastrophic or extreme weather and other natural events and the physical effects of climate change, the occurrence of cyber incidents, effects on global and national markets as well as businesses resulting from increased inflation, rising interest rates, supply chain disruptions, labor conditions, the conflict between Russia and Ukraine, and/or new and ongoing hostilities between Israel and Hamas and the other factors described in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and the Company’s other filings with the Securities and Exchange Commission from time to time. Readers are therefore cautioned not to place undue reliance on the forward-looking statements contained herein which speak only as of the date hereof. The Company intends these forward-looking statements to speak only as of the time of this report and the Company undertakes no obligation to update forward-looking statements, whether as a result of new information, future developments, or otherwise, except as may be required by law.

The purpose of this Management's Discussion and Analysis ("MD&A") is to provide an understanding of the Company's consolidated financial condition, results of operations and cash. MD&A is provided as a supplement to, and should be read in conjunction with, the Company's Condensed Consolidated Financial Statements and accompanying notes.

Overview
References such as "we," "us," "our," and "the Company" mean Community Healthcare Trust Incorporated, a Maryland corporation, and its consolidated subsidiaries.

We were organized in the State of Maryland on March 28, 2014. We are a self-administered, self-managed healthcare real estate investment trust, or REIT, that acquires and owns properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers.

Trends and Matters Impacting Operating Results
Management monitors factors and trends that it believes are important to the Company and the REIT industry in order to gauge their potential impact on the operations of the Company. Certain of the factors and trends that management believes may impact the operations of the Company are discussed below.
23
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
Real Estate Acquisitions
During the first nine months of 2023, the Company acquired 17 real estate properties and a land parcel adjacent to one of our facilities totaling approximately 414,740 square feet for an aggregate purchase price of approximately $90.8 million and cash consideration of approximately $92.0 million. Upon acquisition, the properties were 99.6% leased in the aggregate with lease expirations through 2038. These acquisitions were funded through the Company's free cash flow, proceeds from equity sales through the ATM program, and the Company's Revolving Credit Facility. See Note 4 – Real Estate Acquisitions and Dispositions to the Condensed Consolidated Financial Statements for more details on these acquisitions.

Subsequent Acquisitions
Subsequent to September 30, 2023, the Company acquired two medical office buildings in a single transaction for an aggregate purchase price and cash consideration of approximately $7.1 million. Upon acquisition, the properties were 96.8% leased in the aggregate with lease expirations through 2031.

Acquisition Pipeline
The Company has seven properties under definitive purchase agreements, to be acquired after completion and occupancy, for an aggregate expected purchase price of approximately $166.5 million. The Company's expected return on these investments will approximate 9.1% to 9.75%. The Company anticipates closing on these properties throughout 2024 and 2025; however, the Company cannot provide assurance as to the timing of when, or whether, these transactions will actually close.

Leased Square Footage
As of September 30, 2023, our real estate portfolio was approximately 91.0% leased. During the first nine months of 2023, we had expiring or terminated leases related to approximately 368,000 square feet, and we leased or renewed leases relating to approximately 290,000 square feet.

Purchase Option Provisions
Certain of the Company's leases provide the lessee with a purchase option or a right of first refusal to purchase the leased property. The purchase option provisions generally allow the lessee to purchase the leased property at fair value or at an amount greater than the Company's gross investment in the leased property at the time of the purchase.

At September 30, 2023, the Company had an aggregate gross investment of approximately $40.4 million in 11 real estate properties with purchase options exercisable at September 30, 2023 that had not been exercised.

Inflation
Periods of high and persistent inflation could cause an increase in our expenses, capital expenditures, and cost of our variable-rate borrowings which could have a material impact on our financial position or results of operations. Many of our lease agreements contain provisions designed to mitigate the adverse impact of inflation, including annual rent increases based on stated increases or CPI increases. In response to inflationary pressures, the Federal Reserve began raising interest rates in 2022 and has indicated that it foresees further interest rate increases throughout 2023. Higher interest rates imposed by the Federal Reserve to address inflation may adversely impact real estate asset values and increase our interest expense on our variable-rate borrowings under our revolving credit facility.


Results of Operations
The Company's results of operations for the three and nine months ended September 30, 2023 compared to the same periods in 2022 were impacted by real estate acquisitions, capital market activity, the amortization of non-cash compensation, including the non-cash accelerated amortization of unvested restricted shares upon the passing of the Company's former CEO and President, the accelerated amortization of intangible real estate assets, as well as other items discussed in more detail below.

24
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
Three Months Ended September 30, 2023 Compared to Three Months Ended September 30, 2022
The table below shows our results of operations for the three months ended September 30, 2023 compared to the same period in 2022 and the effect of changes in those results from period to period on our net income.
Three Months Ended September 30, Increase (Decrease) to
Net income
(Dollars in thousands)
 2023 2022 $ %
REVENUES
Rental income
 $ 27,690  $ 23,919  $ 3,771  15.8  %
Other operating interest
 1,045  888  157  17.7  %
28,735  24,807  3,928  15.8  %
EXPENSES
Property operating
 5,456  4,327  (1,129) (26.1) %
General and administrative
 3,618  3,762  144  3.8  %
Depreciation and amortization
 11,208  8,003  (3,205) (40.0) %
20,282  16,092  (4,190) (26.0) %
INCOME BEFORE INCOME TAXES AND OTHER ITEMS
 8,453  8,715  (262) (3.0) %
Impairment of real estate asset
 (102) —  (102) n/m
Interest expense
 (4,641) (3,028) (1,613) (53.3) %
Deferred income tax expense
 (221) (21) (200) n/m
Interest and other income
 3  7  (4) n/m
NET INCOME
$ 3,492  $ 5,673  $ (2,181) (38.4) %
n/m - not meaningful

Revenues
Rental income increased approximately $3.8 million, or 15.8%, for the three months ended September 30, 2023 compared to the same period in 2022 due mainly to rental income on properties acquired during 2022 and 2023.

Other operating interest increased $0.2 million, or 17.7%, for the three months ended September 30, 2023 compared to the same period in 2022 due mainly to additional amounts funded under existing notes receivable.

Expenses
Property operating expenses increased approximately $1.1 million, or 26.1%, for the three months ended September 30, 2023 compared to the same period in 2022. Expenses on properties acquired during 2022 and 2023 increased property operating expenses by approximately $0.8 million. The remainder of the increase in property operating expenses related to various increases in expenses such as maintenance and repairs of $0.2 million and the amortization of leasing commissions of $0.1 million.

General and administrative expenses decreased approximately $0.1 million, or 3.8%, for the three months ended September 30, 2023 compared to the same period in 2022. Compensation expense decreased approximately $0.3 million for the three months ended September 30, 2023 compared to the same period in 2022, of which approximately $0.6 million related to a decrease in non-cash amortization of stock-based compensation, offset partially by an increase of approximately $0.3 million related mainly to new employees and salary increases. Also, professional fees increased approximately $0.1 million for the three months ended September 30, 2023 compared to the same period in 2022 related to an increase in legal fees.

Depreciation and amortization expense increased approximately $3.2 million, or 40.0%, for the three months ended September 30, 2023 compared to the same period in 2022. This increase was comprised mainly of the following:

•Acquisitions of real estate in 2022 and 2023 resulted in an increase of approximately $1.8 million;
25
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
•Accelerated amortization of lease intangibles on the two GenesisCare properties where the leases have been rejected totaled approximately $1.5 million;
•Tenant improvements and other capital expenditures resulted in an increase of approximately $0.4 million; and
•Fully amortized real estate lease intangibles which generally have a shorter depreciable life than a building resulted in a decrease of approximately $0.4 million.

Impairment of real estate asset
During the three months ended September 30, 2023, the Company recorded an impairment on an asset held for sale of approximately $0.1 million. See Note 4 to the Condensed Consolidated Financial Statements for more detail.

Interest expense
Interest expense increased approximately $1.6 million, or 53.3%, for the three months ended September 30, 2023 compared to the same period in 2022. Interest due under the Credit Facility increased approximately $1.6 million due mainly to the Credit Facility refinancing in the fourth quarter of 2022 (See Note 5 to the Condensed Consolidated Financial Statements), along with an increase in the revolving credit facility balance and a rise in interest rates.

Deferred income tax expense
Deferred income tax expense increased approximately $0.2 million for the three months ended September 30, 2023 compared to the same period in 2022. During the three months ended September 30, 2023, the Company recorded an additional $0.2 million valuation allowance on its deferred tax asset.

Nine Months Ended September 30, 2023 Compared to Nine Months Ended September 30, 2022
The table below shows our results of operations for the nine months ended September 30, 2023 compared to the same period in 2022 and the effect of changes in those results from period to period on our net income.
Nine Months Ended
September 30,		 Increase (Decrease) to
Net income
(Dollars in thousands)
 2023 2022 $ %
REVENUES
Rental income
 $ 80,582  $ 69,720  $ 10,862  15.6  %
Other operating interest
 3,139  2,617  522  19.9  %
83,721  72,337  11,384  15.7  %
EXPENSES
Property operating
 15,115  12,480  (2,635) (21.1) %
General and administrative
 23,610  10,688  (12,922) n/m
Depreciation and amortization
 29,445  24,022  (5,423) (22.6) %
68,170  47,190  (20,980) (44.5) %
INCOME BEFORE INCOME TAXES AND OTHER ITEMS
 15,551  25,147  (9,596) (38.2) %
Impairment of real estate asset
 (102) —  (102) n/m
Interest expense
 (12,773) (8,409) (4,364) (51.9) %
Deferred income tax expense
 (306) (20) (286) n/m
Interest and other income
 777  63  714  n/m
NET INCOME
$ 3,147  $ 16,781  $ (13,634) (81.2) %
n/m - not meaningful


26
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
Revenues
Rental income increased approximately $10.9 million, or 15.6%, for the nine months ended September 30, 2023 compared to the same period in 2022. Income on properties acquired during 2022 and 2023 increased rental income by approximately $10.7 million.

Other operating interest increased $0.5 million, or 19.9%, for the nine months ended September 30, 2023 compared to the same period in 2022 due mainly to additional amounts funded under existing notes receivable.

Expenses
Property operating expenses increased approximately $2.6 million, or 21.1%, for the nine months ended September 30, 2023 compared to the same period in 2022. Expenses on properties acquired during 2022 and 2023 increased property operating expenses by approximately $2.0 million. The remainder of the increase in property operating expenses totaling $0.6 million related to various increases in expenses such as maintenance and repairs of $0.3 million, security monitoring of $0.1 million, property insurance of $0.1 million and the amortization of leasing commissions of $0.1 million.

General and administrative expenses increased approximately $12.9 million for the nine months ended September 30, 2023 compared to the same period in 2022 due to several factors. In accordance with the terms of the Company's former CEO and President's employment agreement upon his passing, the Company accelerated the unamortized remaining balance of deferred compensation related to his unvested shares and recognized an additional $11.8 million of non-cash amortization expense in the first quarter of 2023. Also, compensation expense increased approximately $0.4 million for the nine months ended September 30, 2023 compared to the same period in 2022, of which approximately $0.3 million related to the payment of employer taxes due upon the accelerated vesting of the Company's former CEO and President's shares, and $0.7 million related mainly to new employees and salary increases, offset partially by a decrease in non-cash amortization of stock-based compensation of approximately $0.6 million. Further, professional fees increased approximately $0.6 million for the nine months ended September 30, 2023 compared to the same period in 2022, of which $0.2 million related to audit and accounting fees and $0.4 million related mainly to legal fees. The increase in legal fees was largely related to the passing of our former CEO and President, including related executive and board matters.

Depreciation and amortization expense increased approximately $5.4 million, or 22.6%, for the nine months ended September 30, 2023 compared to the same period in 2022. This increase was comprised mainly of the following:

•Acquisitions of real estate in 2022 and 2023 resulted in an increase of approximately $4.6 million;
•Tenant improvements and other capital expenditures resulted in an increase of approximately $0.8 million;
•Accelerated amortization of lease intangibles on the two GenesisCare properties where the leases have been rejected totaled approximately $1.5 million; and
•Fully amortized real estate lease intangibles which generally have a shorter depreciable life than a building resulted in a decrease of approximately $1.3 million.

Impairment of real estate asset
During the nine months ended September 30, 2023, the Company recorded an impairment on an asset held for sale of approximately $0.1 million. See Note 4 to the Condensed Consolidated Financial Statements for more detail.

Interest expense
Interest expense increased approximately $4.4 million, or 51.9%, for the nine months ended September 30, 2023 compared to the same period in 2022. Interest due under the Credit Facility increased approximately $4.3 million due to the Credit Facility refinancing in the fourth quarter of 2022 (See Note 5 to the Condensed Consolidated Financial Statements), along with an increase in the revolving credit facility balance and a rise in interest rates.


27
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
Deferred income tax expense
Deferred income tax expense increased approximately $0.3 million for the nine months ended September 30, 2023 compared to the same period in 2022. During the three months ended September 30, 2023, the Company recorded an additional $0.2 million valuation allowance on its deferred tax asset.

Interest and other income
Interest and other income increased approximately $0.7 million for the nine months ended September 30, 2023 compared to the same period in 2022. During the three months ended June 30, 2023, the Company recognized a net casualty gain relating to a property totaling $0.7 million. See Note 4 to the Condensed Consolidated Financial Statements for more detail.

Non-GAAP Financial Measures and Key Performance Indicators
Management considers certain non-GAAP financial measures and key performance indicators to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. The Company reports non-GAAP financial measures because these measures are observed by management to also be among the most predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these non-GAAP financial measures. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors, as well as reconciliations of those measures to the most directly comparable GAAP financial measure.

The non-GAAP financial measures and key performance indicators presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented in the Condensed Consolidated Financial Statements and other financial data included elsewhere in this Quarterly Report on Form 10-Q.

Funds from Operations ("FFO") and Adjusted Funds from Operations ("AFFO")
FFO is an operating performance measure adopted by the National Association of Real Estate Investment Trusts, Inc. (“NAREIT”). NAREIT defines FFO as the most commonly accepted and reported measure of a REIT’s operating performance equal to net income (calculated in accordance with GAAP), excluding gains or losses from the sale of certain real estate assets, gains and losses from change in control, impairment write-downs of certain real estate assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity, plus depreciation and amortization related to real estate properties, and after adjustments for unconsolidated partnerships and joint ventures. NAREIT also provides REITs with an option to exclude gains, losses and impairments of assets that are incidental to the main business of the REIT from the calculation of FFO.

In addition to FFO, the Company presents AFFO and AFFO per share. The Company defines AFFO as FFO, excluding certain expenses related to closing costs of properties acquired accounted for as business combinations and mortgages funded, excluding straight-line rent and the amortization of stock-based compensation, and including or excluding other non-cash items from time to time. AFFO presented herein may not be comparable to similar measures presented by other real estate companies due to the fact that not all real estate companies use the same definition.

28
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
Management believes that net income, as defined by GAAP, is the most appropriate earnings measurement. However, management believes FFO, AFFO, FFO per share and AFFO per share provide an understanding of the operating performance of the Company’s properties without giving effect to certain significant non-cash items, primarily depreciation and amortization expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. The Company believes that by excluding the effect of depreciation, amortization, impairments and gains or losses from sales of real estate, losses and impairment of incidental assets, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, FFO, AFFO, FFO per share and AFFO per share can facilitate comparisons of operating performance between periods.

The table below reconciles net income to FFO and AFFO for the three months ended September 30, 2023 compared to the same period in 2022.
Three Months Ended
September 30,
(In thousands, except per share amounts) 2023 2022
Net income $ 3,492  $ 5,673 
Real estate depreciation and amortization
 11,375  8,078 
Impairment of real estate asset
 102  — 
FFO 14,969  13,751 
Straight-line rent
 (444) (853)
Stock-based compensation
 1,898  2,464 
AFFO $ 16,423  $ 15,362 
FFO per diluted common share $ 0.58  $ 0.57 
AFFO per diluted common share $ 0.63  $ 0.63 
Weighted average common shares outstanding - diluted (1)
 26,025  24,312 
___________________

(1) Diluted weighted average common shares outstanding for FFO and AFFO are calculated based on the treasury method, rather than the 2-class method used to calculate earnings per share.

Net Operating Income ("NOI")
NOI is a key performance indicator. NOI is defined as net income or loss, computed in accordance with GAAP, generated from our total portfolio of properties and other investments before general and administrative expenses, depreciation and amortization expense, gains or loss on the sale of real estate properties or other investments, interest expense, and income tax expense. We believe that NOI provides an accurate measure of operating performance of our operating assets because NOI excludes certain items that are not associated with management of the properties. The Company's use of the term NOI may not be comparable to that of other real estate companies as they may have different methodologies for computing NOI.

The table below reconciles net income to NOI for the three months ended September 30, 2023 compared to the same period in 2022.
29
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
Three Months Ended
September 30,
(In thousands) 2023 2022
Net income $ 3,492  $ 5,673 
General and administrative 3,618  3,762 
Depreciation and amortization 11,208  8,003 
Impairment of real estate asset 102  — 
Interest expense 4,641  3,028 
Deferred income tax expense 221  21 
Interest and other income (3) (7)
NOI $ 23,279  $ 20,480 

EBITDAre and Adjusted EBITDAre
The Company uses the NAREIT definition of EBITDAre which is net income or loss plus interest expense, income tax expense, and depreciation and amortization, plus losses or minus gains on the disposition of depreciable property, including losses/gains on change of control, plus impairment write-downs of depreciable property and of investments in unconsolidated affiliates caused by a decrease in value of depreciable property in the affiliate, plus or minus adjustments to reflect the entity's share of EBITDAre of unconsolidated affiliates and consolidated affiliates with non-controlling interest. The Company also presents Adjusted EBITDAre which is EBITDAre before non-cash stock-based compensation expense.

We consider EBITDAre and Adjusted EBITDAre important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.

The table below reconciles net income to EBITDAre and Adjusted EBITDAre for the three months ended September 30, 2023 compared to the same period in 2022.

Three Months Ended
September 30,
(In thousands) 2023 2022
Net income $ 3,492  $ 5,673 
Interest expense 4,641  3,028 
Depreciation and amortization 11,208  8,003 
Deferred income tax expense 221  21 
Impairment of real estate asset 102  — 
EBITDAre
 $ 19,664  $ 16,725 
Non-cash stock-based compensation expense 1,898  2,464 
Adjusted EBITDAre
 $ 21,562  $ 19,189 
Liquidity and Capital Resources
The Company monitors its liquidity and capital resources and relies on several key indicators in its assessment of capital markets for financing acquisitions and other operating activities as needed, including the following:

•Leverage ratios and financial covenants included in our Credit Facility;

•Dividend payout percentage; and

•Interest rates, underlying treasury rates, debt market spreads and equity markets.

30
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
The Company uses these indicators and others to compare its operations to its peers and to help identify areas in which the Company may need to focus its attention.

Financing Policy
The Company’s current financing policy prohibits aggregate debt (secured or unsecured) in excess of 40% of the Company's total capitalization, except for short-term, transitory periods. At September 30, 2023, our debt to total capitalization ratio (debt plus stockholders' equity plus accumulated depreciation) was approximately 35.9%.

Sources and Uses of Cash
The Company derives most of its revenues from its real estate properties. Our rental income represents our primary source of liquidity to fund our dividends, general and administrative expenses, property operating expenses, capital improvements on our properties, interest expense on our Credit Facility, and other expenses incurred related to managing our existing portfolio. To the extent additional resources are needed, the Company will fund its investment activity generally through equity or debt issuances either in the public or private markets or through proceeds from our Credit Facility.

The Company expects to meet its liquidity needs through cash on hand, cash flows from operations and cash flows from sources discussed above. The Company believes that its liquidity and sources of capital are adequate to satisfy its cash requirements. The Company cannot, however, be certain that these sources of funds will be available at a time and upon terms acceptable to the Company in sufficient amounts to meet its liquidity needs.

Credit Facility
The Company's first amendment (the "First Amendment") to the third amended and restated credit facility (the "Credit Facility") provides for a $150.0 million Revolving Credit Facility that matures on March 19, 2026 and includes one 12-month option to extend the maturity date, and $350.0 million in Term Loans, as well as an accordion feature which allows borrowings up to a total of $700.0 million, including the ability to add and fund additional term loans. Note 5 – Debt, net to the Condensed Consolidated Financial Statements provides more details on the Company's Credit Facility. At September 30, 2023, the Company had borrowing capacity remaining under the Revolving Credit Facility of approximately $102.0 million.

The Company’s ability to borrow under the Credit Facility is subject to its ongoing compliance with a number of customary affirmative and negative covenants, including limitations with respect to liens, indebtedness, distributions, mergers, consolidations, investments, restricted payments and asset sales, as well as financial maintenance covenants. The Company was in compliance with its financial covenants under its Credit Facility as of September 30, 2023.

Mortgage Note Payable
The Company also had outstanding at September 30, 2023, a $4.9 million mortgage note payable, secured by one of its properties. The mortgage note amortizes monthly at a fixed interest rate of 4.98% with a balloon payment of approximately $4.8 million due upon maturity on May 1, 2024. The Company expects to fund the balloon payment with proceeds from the Company's ATM Program or proceeds from the Company's Revolving Credit Facility.

Ground Leases
At September 30, 2023, the Company was obligated, as the lessee, under four non-prepaid ground leases accounted for as operating leases with expiration dates, including renewal options, through 2076, and two non-prepaid ground leases accounted for as financing leases with expiration dates through 2109, including renewal options. Any rental increases related to the Company's ground leases are generally either stated or based on the Consumer Price Index. At September 30, 2023, the Company's aggregate obligation under these ground leases was approximately $8.9 million. See Note 3 – Real Estate Leases to the Condensed Consolidated Financial Statements.



31
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
Subsequent Acquisitions
Subsequent to September 30, 2023, the Company acquired two medical office buildings for a purchase price of approximately $7.1 million and cash consideration of approximately $7.1 million. Upon acquisition, the properties were 96.8% leased with lease expirations through 2031. These acquisitions were funded through the Company's free cash flow, proceeds from equity sales through the ATM program, and the Company's Revolving Credit Facility.

Acquisition Pipeline
The Company has seven properties under definitive purchase agreements, to be acquired after completion and occupancy, for an aggregate expected purchase price of approximately $166.5 million. The Company's expected return on these investments will approximate 9.1% to 9.75%. The Company anticipates closing on these properties throughout 2024 and 2025; however, the Company cannot provide assurance as to the timing of when, or whether, these transactions will actually close. The Company expects to fund these acquisitions through the Company's free cash flow, proceeds from equity sales through the ATM program, and the Company's Revolving Credit Facility.

Tenant Improvements and Capital Improvements
Subject to Company approval, we may fund or reimburse tenants for tenant improvements, which are allowed for in certain leases, of up to approximately $11.5 million as of September 30, 2023.

The Company has also entered into contracts regarding certain capital expenditures with remaining commitments totaling approximately $6.3 million as of September 30, 2023. Reimbursement of these expenditures by our tenants will be determined by each tenant's lease.

The Company expects to fund these expenditures through the Company's free cash flow, proceeds from equity sales through the ATM program, and the Company's Revolving Credit Facility.

Notes Receivable
The Company had entered into notes with one tenant with a maximum commitment remaining to fund totaling $5.1 million at September 30, 2023. See Note 10 – Other Assets, net to the Condensed Consolidated Financial Statements.

Automatic Shelf Registration Statement
On November 2, 2022, the Company filed an automatic shelf registration statement on Form S-3 with the Securities and Exchange Commission. The registration statement is for an indeterminate number of securities and is effective for three years. Under this registration statement, the Company has the capacity to offer and sell from time to time various types of securities, including common stock, preferred stock, depository shares, rights, debt securities, warrants and units.

Operating Activities
Cash flows provided by operating activities for the nine months ended September 30, 2023 and 2022 were approximately $47.1 million and $44.9 million, respectively. Cash flows provided by operating activities were generally provided by contractual rents and interest on our notes receivable, net of property operating expenses not reimbursed by the tenants and general and administrative expenses.

Investing Activities
Cash flows used in investing activities for the nine months ended September 30, 2023 and 2022 were approximately $100.1 million and $55.9 million, respectively. During the nine months ended September 30, 2023, the Company invested in 17 properties and one land parcel for an aggregate cash consideration of approximately $92.0 million and funded notes totaling approximately $2.0 million. Also, during the nine months ended September 30, 2023, the Company received payments on its notes totaling $3.0 million, received insurance proceeds from a casualty loss totaling $2.3 million, and funded capital expenditures on its existing portfolio totaling approximately $11.5 million.

32
Management's Discussion and Analysis of Financial Condition and Results of Operations - Continued
During the nine months ended September 30, 2022, the Company invested in three properties for an aggregate cash consideration of approximately $46.0 million and funded notes receivable totaling approximately $5.5 million. Also, during the nine months ended September 30, 2022, the Company received payments on its notes receivable totaling $2.3 million and funded capital expenditures on its existing portfolio totaling approximately $6.7 million.

Financing Activities
Cash flows provided by financing activities for the nine months ended September 30, 2023 and 2022 were approximately $45.9 million and $11.5 million, respectively. During the nine months ended September 30, 2023, the Company (i) borrowed $48.0 million under its Revolving Credit Facility, (ii) completed equity offerings under its at-the-market program, resulting in net proceeds, net of underwriters' discount and offering costs, of approximately $34.6 million, (iii) upon the vesting of stock-based awards for certain employees, withheld shares and paid taxes totaling approximately $1.0 million on behalf of the employees, and (iv) paid dividends totaling approximately $35.6 million.

During the nine months ended September 30, 2022, the Company borrowed $45.0 million under its Revolving Credit Facility and paid dividends totaling approximately $33.2 million.

Security Deposits
As of September 30, 2023, the Company held approximately $3.6 million in security deposits for the benefit of the Company in the event the obligated tenant fails to perform under the terms of its respective lease. Generally, the Company may, at its discretion and upon notification to the tenant, draw upon the security deposits if there are any defaults under the leases.

Dividends
The Company is required to pay dividends to its stockholders at least equal to 90% of its taxable income in order to maintain its qualification as a REIT.

On October 26, 2023, the Company’s Board of Directors declared a quarterly common stock dividend in the amount of $0.455 per share. The dividend is payable on November 24, 2023 to stockholders of record on November 9, 2023. This rate equates to an annualized dividend of $1.82 per share.

The ability of the Company to pay dividends is dependent upon its ability to generate cash flows and to make accretive new investments.

Corporate Responsibility
The Company is committed to conducting its business according to the highest ethical standards and upholding its corporate responsibilities as a public company operating for the benefit of its stockholders. To that end, the Company modified its Governance Committee to be the Environmental, Social, and Governance (“ESG”) Committee with a revised charter included on the Company’s website at www.chct.reit. Among other duties, the ESG Committee meets at least annually to review and recommend to the Board the general strategy and initiatives regarding ESG matters, including the Company’s internal and external communications and disclosures.

The Company’s Board of Directors has adopted a revised Code of Ethics and Business Conduct that not only applies to its directors, officers, and other employees but also extends the Company's expectations that its vendors, service providers, contractors, and consultants will embrace the Company's commitment to integrity and personal responsibility by complying with this Code at all times. The Code of Ethics and Business Conduct includes the Company’s commitment to promote high standards of integrity by conducting its affairs honestly and ethically and to include in its periodic reports or other publicly available documents information and metrics related to internal monitoring, whistleblower, or reporting systems.

The Company’s whistleblower policy prohibits the Company and its affiliates and their officers, employees and agents from discharging, demoting, suspending, threatening, harassing or in any other manner discriminating against any employee for raising a concern. If an employee desires to raise a concern in a confidential or anonymous manner, the concern may be directed to the whistleblower officer at the Company’s whistleblower hotline.
33

During the quarter ended September 30, 2023, the whistleblower officer received no whistleblower complaints.

The Company’s Information Technology infrastructure is cloud-based, utilizing Software as a Service (“SaaS”) applications for substantially all of its software requirements. Management has formed an IT Committee consisting of the Chief Executive Officer, Chief Financial Officer, and the Vice President of Information Technology to review and discuss information security matters and cyber security risks. The committee meets at least twice a year and reports to the Board of Directors as needed. The Company has adopted the Center of Internet Security (CIS) v8 IG1 cyber security controls including adopting an annual information security training program for its employees. The Company has partnered with a global cyber security leader to continuously and proactively manage and mitigate the ever growing list of cyber threats. As part of the managed monitoring and remediation platform, the Company benefits from a $100,000 breach prevention warranty. Since the Company’s inception, the Company has not had a security breach resulting in expenses, penalties or settlements.

34


ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our future income, cash flows and fair values relevant to financial instruments are dependent upon prevailing market interest rates. Market risk refers to the risk of loss from adverse changes in market prices and interest rates. We may use certain derivative financial instruments to manage, or hedge, interest rate risks related to our borrowings. We will not use derivatives for trading or speculative purposes and only enter into contracts with major financial institutions based upon their credit rating and other factors. An interest rate swap is a contractual agreement entered into by two counterparties under which each agrees to make periodic payments to the other for an agreed period of time based on a notional amount of principal. Under the most common form of interest rate swap, known from our perspective as a floating-to-fixed interest rate swap, a series of floating, or variable, rate payments on a notional amount of principal is exchanged for a series of fixed interest rate payments on such notional amount. During the nine months ended September 30, 2023, there were no material changes in the quantitative and qualitative disclosures about market risks presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this report. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer has concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective.

Changes In Internal Control Over Financial Reporting
There were no changes in our system of internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

35

PART II. OTHER INFORMATION

ITEM 1.    LEGAL PROCEEDINGS

The Company may, from time to time, be involved in litigation arising in the ordinary course of business or which may be expected to be covered by insurance. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

ITEM 1A.    RISK FACTORS

In addition to the other information set forth in this Quarterly Report on Form 10-Q, an investor should consider the risk factors included in its Annual Report on Form 10-K for the year ended December 31, 2022 and other reports that may be filed by the Company. There were no material changes in the risk factors presented in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.

ITEM 2.   UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.   DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.   MINE SAFETY DISCLOSURES

None.

ITEM 5.   OTHER INFORMATION

During the quarter ended September 30, 2023, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).


36

ITEM 6.    EXHIBITS
The exhibits required by Item 601 of Regulation S-K which are filed with this report are listed in the Exhibit Index and are hereby incorporated in by reference.
EXHIBIT INDEX
Exhibit No.
 Description
3.1
3.2
31.1 *
31.2 *
32.1 **
101.INS Inline XBRL Instance Document
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Labels Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
___________________
(1)Filed as Exhibit 3.1 to Amendment No. 2 to the Registration Statement on Form S-11 of the Company filed with the Securities and Exchange Commission on May 6, 2015 (Registration No. 333-203210) and incorporated herein by reference.
(2)Filed as Exhibit 3.2 to the Quarterly Report on Form 10-Q of the Company filed with the Securities and Exchange Commission on November 3, 2020 (File No. 001-37401) and incorporated herein by reference.

*    Filed herewith.
**    Furnished herewith.


37

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: October 31, 2023
COMMUNITY HEALTHCARE TRUST INCORPORATED
By: /s/ David H. Dupuy
David H. Dupuy
Chief Executive Officer and President
By: /s/ William G. Monroe IV
William G. Monroe IV
Executive Vice President and Chief Financial Officer
38
EX-31.1 2 chct-20230930xexhibitx311.htm EX-31.1 Document

Exhibit 31.1

Community Healthcare Trust Incorporated
Quarterly Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, David H. Dupuy, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Community Healthcare Trust Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: October 31, 2023
/s/ David H. Dupuy
David H. Dupuy
Chief Executive Officer and President

EX-31.2 3 chct-20230930xexhibitx312.htm EX-31.2 Document

Exhibit 31.2

Community Healthcare Trust Incorporated
Quarterly Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, William G. Monroe IV, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Community Healthcare Trust Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: October 31, 2023
/s/ William G. Monroe IV
William G. Monroe IV
Executive Vice President and Chief Financial Officer

EX-32.1 4 chct-20230930xexhibitx321.htm EX-32.1 Document

Exhibit 32.1

Community Healthcare Trust Incorporated
Certification Pursuant to
18 U.S.C. Section 1350,
as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q of Community Healthcare Trust Incorporated (the "Company") for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, David H. Dupuy, Chief Executive Officer and President of the Company, and I, William G. Monroe IV, Executive Vice President and Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
i.The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
ii.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: October 31, 2023
/s/ David H. Dupuy
David H. Dupuy
Chief Executive Officer and President
/s/ William G. Monroe IV
William G. Monroe IV
Executive Vice President and
Chief Financial Officer